Clinical trials: Metabolic-dysfunction Associated Steatotic Liver Disease
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
- Trial name
- NCT06482112
- Testing
- Efinopegdutide
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 124 people
- Sponsor
- Merck Sharp & Dohme LLC
Fatty Liver, Nonalcoholic, Weight Loss
Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease
Metabolic-dysfunction associated steatotic liver disease, often referred to as "fatty liver disease", is a leading cause of liver failure.
- Conditions
- Fatty Liver, Nonalcoholic, Weight Loss, Virtual Reality, Implementation Science
- Trial name
- NCT06215131
- Testing
- In-person dietary weight loss counseling, Virtual reality dietary weight loss counseling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Milton S. Hershey Medical Center
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NAFLD, Metabolic Dysfunction-associated Steatotic Liver Disease
- Trial name
- NCT06465186
- Testing
- Efinopegdutide
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 85 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease
Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population
The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease, Biological Age
- Trial name
- NCT06984510
- Testing
- Observational
- Where
- China
- Volunteers
- 2,720 people
- Sponsor
- Ningbo No. 1 Hospital
Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
Liver Fibrosis Assessment in Diabetic Patients
The investigators plan to use the smartphone App for FIB-4 calculation and increase the awareness of liver fibrosis. These patients might notify and discuss with the physician of their liver fibrosis severity to improve the…
- Trial name
- NCT06694974
- Testing
- APP calculation for FIB-4, Standard Care (in control arm)
- Where
- Taiwan
- Volunteers
- 540 people
- Sponsor
- National Taiwan University Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease
Study of Metabolic Dysfunction-Associated Steatotic Liver Disease Among Sohag University Employees
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for steatotic liver disease associated with metabolic syndrome.
- Trial name
- NCT06536933
- Testing
- Abdominal Ultrasound
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease NAFLD
Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver condition linked to excess body fat, high blood lipids, and other metabolic problems.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease NAFLD, Dyslipidemia, Obesity & Overweight
- Trial name
- TGP-MASLD (NCT07692438)
- Testing
- Taiwan green propolis capsule
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Medical University
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Assessment of Non-Invasive Testing in Major Liver-Related Outcomes
This is a general clinical research protocol to study the clinical evaluation, investigation and long-term follow up of patients who have Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MetALD (MASLD and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Trial name
- MAIL-NIT (NCT06986447)
- Where
- 8 sites in United States
- Volunteers
- 1,689 people
- Sponsor
- HRI-MAIL-NIT
Cardiac Arrhythmia, Metabolic Dysfunction Associated Steatotic Liver Disease
Pattern of Cardiac Arrhythmia in Patients With MASLD
Study the relationship between patients with MASLD and cardiac arrhythmia that could be occur in thos patients
- Trial name
- NCT06490432
- Testing
- Transient elastography
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Obesity, Liver Diseases
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting…
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat
- Trial name
- NCT06138821
- Testing
- ESG + lifestyle modification, Lifestyle modification
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Pichamol Jirapinyo, MD, MPH
Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a chronic, metabolic liver disease that is closely related to obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) in a bidirectional mode.
- Trial name
- OsteoNAFLD (NCT05493761)
- Testing
- Denosumab, Alendronate Sodium
- Where
- 3 sites in Greece
- Volunteers
- 72 people
- Sponsor
- Aristotle University Of Thessaloniki
Metabolic Dysfunction-Associated Steatotic Liver Disease, Childhood Obesity
Lifestyle Habits and Metabolic Dysfunction-Associated Steatotic Liver Disease in Youth
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease in children and adolescents.
- Trial name
- LIFE4MASLD (NCT07095010)
- Where
- Greece
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Harokopio University
Metabolic Dysfunction-Associated Steatotic Liver Disease
Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).
The goal of this observational study is to create a detailed virtual model to better understand how Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) develops.
- Trial name
- ARTEMIS (NCT07430501)
- Testing
- Data recollection
- Where
- Spain
- Volunteers
- 7,720 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis
Quantitative Ultrasound (RS85 and R20) for Liver Fat Quantification in MASLD Using MRI-PDFF as Reference
This multicenter prospective study aims to evaluate the correlation between quantitative ultrasound fat fraction (USFF) and MRI-PDFF (Proton Density Fat Fraction) for liver fat quantification in patients with metabolic…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatic Steatosis, Liver Disease Parenchymal
- Trial name
- DeepUSFF (NCT07192159)
- Testing
- Quantitative ultrasound (DeepUSFF)
- Where
- 2 sites in United States, South Korea
- Volunteers
- 182 people
- Sponsor
- Seoul National University Hospital
Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults MASLD Patients (DELI_MASLD Study)
The current study aim was to conduct placebo-controlled randomize clinical trial to assess the short-term efficacy and safety of postbiotics on hepatic fat content as measured by biochemichal hepatic steatosis indeces, serum…
- Conditions
- Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease, Hepatic Steatosis
- Trial name
- NCT06352697
- Testing
- Probiotic lysate (postbiotic and metabiotc)
- Where
- 5 sites in Ukraine
- Volunteers
- 52 people
- Sponsor
- Bogomolets National Medical University
Food Insecurity
Implementing Food Referrals for Equity and Sustained Health
Food insecurity (FI) disproportionately affects those who have been historically marginalized and significantly contributes to poor health outcomes.
- Trial name
- I-FRESH (NCT06661538)
- Testing
- Food Security Screening & Referral Program
- Where
- 2 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Metabolic Flux Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease
This prospective, single-center pilot study will evaluate metabolic flux dysregulation in adults with obesity and suspected or confirmed metabolic dysfunction-associated steatotic liver disease (MASLD) who are scheduled for…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Obesity, Bariatric Surgery
- Trial name
- MASLD (NCT07760909)
- Testing
- Bariatric surgery, Stable isotope tracer infusion, MRI/MRE
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University Medical Center
Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Short-term Perioperative Daidzein Intervention on Liver Histopathology in Patients With MASLD
This clinical trial aims to learn whether daidzein can improve liver tissue changes in adults with metabolic dysfunction-associated steatotic liver disease, also called MASLD.
- Trial name
- DAIMAS (NCT07623044)
- Testing
- Daidzein
- Volunteers
- 44 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Metabolic Dysfunction-associated Steatotic Liver Disease
Digital Pathology and AI for Liver Outcomes in MASLD
The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital…
- Trial name
- DPAILO-1 (NCT06344364)
- Testing
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Where
- 3 sites in Hong Kong, Spain
- Volunteers
- 1,241 people
- Sponsor
- PharmaNest, Inc
Metabolic Dysfunction-Associated Steatotic Liver Disease
Efficacy and Safety of Rifaximin-α in Treating MASLD
Study Objective: To evaluate the efficacy and safety of Rifaximin-α in the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and investigate the underlying mechanisms by which Rifaximin-α influences…
- Trial name
- NCT07381257
- Testing
- Rifaximin-α (Alfa Wassermann S.p.A., Italy)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Changzheng Hospital